Amgen Inc. Payments to Acquire Marketable Securities
Amgen Inc. (AMGN) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-02-14
- Amgen Inc. payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. payments to acquire marketable securities for the quarter ending 2023-09-30 was $1.00M, a 99.74% decline year-over-year.
- Amgen Inc. payments to acquire marketable securities for the quarter ending 2022-12-31 was $224.00M.
- Amgen Inc. payments to acquire marketable securities for the quarter ending 2022-09-30 was $387.00M, a 57.05% decline year-over-year.
- Amgen Inc. payments to acquire marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Amgen Inc. payments to acquire marketable securities for fiscal 2023 was $1.00M, a 99.96% decline from fiscal 2022.
- Amgen Inc. payments to acquire marketable securities for fiscal 2022 was $2.59B, a 70.93% decline from fiscal 2021.
- Amgen Inc. payments to acquire marketable securities for fiscal 2021 was $8.90B, a 4.99% increase from fiscal 2020.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $1.00M derived: sum of 2 quarters · filed 2025-02-14 | $1.00M 10-K · filed 2025-02-14 | |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $1.00M 10-Q · filed 2023-10-31 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-04 | |||
| 2022-12-31 | $224.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $611.00M derived: sum of 2 quarters · filed 2025-02-14 | $2.59B derived: sum of 3 quarters · filed 2025-02-14 | $2.59B 10-K · filed 2025-02-14 |
| 2022-09-30 | $387.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $2.36B derived: sum of 2 quarters · filed 2023-10-31 | $2.36B 10-Q · filed 2023-10-31 | $2.36B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $1.98B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.98B 10-Q · filed 2023-08-04 | $1.98B derived: sum of 3 quarters · filed 2024-02-14 | $2.88B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $0.00 10-Q · filed 2022-04-28 | -$1.00M derived: sum of 2 quarters · filed 2024-02-14 | $900.00M derived: sum of 3 quarters · filed 2024-02-14 | $1.30B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $900.00M derived: sum of 2 quarters · filed 2024-02-14 | $1.30B derived: sum of 3 quarters · filed 2024-02-14 | $8.90B 10-K · filed 2024-02-14 |
| 2021-09-30 | $901.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.30B derived: sum of 2 quarters · filed 2022-11-04 | $8.90B 10-Q · filed 2022-11-04 | $12.05B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $403.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $8.00B 10-Q · filed 2022-08-05 | $11.15B derived: sum of 3 quarters · filed 2023-02-09 | $14.25B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $7.60B 10-Q · filed 2022-04-28 | $10.74B derived: sum of 2 quarters · filed 2023-02-09 | $13.85B derived: sum of 3 quarters · filed 2023-02-09 | $15.95B derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $3.15B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $6.25B derived: sum of 2 quarters · filed 2023-02-09 | $8.35B derived: sum of 3 quarters · filed 2023-02-09 | $8.48B 10-K · filed 2023-02-09 |
| 2020-09-30 | $3.10B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $5.20B derived: sum of 2 quarters · filed 2021-11-03 | $5.33B 10-Q · filed 2021-11-03 | $5.66B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $2.10B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.23B 10-Q · filed 2021-08-04 | $2.56B derived: sum of 3 quarters · filed 2022-02-16 | $4.37B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $129.00M 10-Q · filed 2021-04-28 | $461.00M derived: sum of 2 quarters · filed 2022-02-16 | $2.27B derived: sum of 3 quarters · filed 2022-02-16 | $2.63B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $332.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.14B derived: sum of 2 quarters · filed 2022-02-16 | $2.50B derived: sum of 3 quarters · filed 2022-02-16 | $9.39B 10-K · filed 2022-02-16 |
| 2019-09-30 | $1.81B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.16B derived: sum of 2 quarters · filed 2020-10-29 | $9.06B 10-Q · filed 2020-10-29 | $15.19B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $352.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $7.25B 10-Q · filed 2020-07-29 | $13.37B derived: sum of 3 quarters · filed 2021-02-09 | $19.26B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $6.90B 10-Q · filed 2020-05-01 | $13.02B derived: sum of 2 quarters · filed 2021-02-09 | $18.91B derived: sum of 3 quarters · filed 2021-02-09 | $22.91B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $6.12B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $12.01B derived: sum of 2 quarters · filed 2021-02-09 | $16.01B derived: sum of 3 quarters · filed 2021-02-09 | $18.74B 10-K · filed 2021-02-09 |
| 2018-09-30 | $5.88B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $9.88B derived: sum of 2 quarters · filed 2019-10-30 | $12.62B 10-Q · filed 2019-10-30 | $19.56B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $4.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $6.73B 10-Q · filed 2019-07-31 | $13.68B derived: sum of 3 quarters · filed 2020-02-12 | $21.10B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $2.73B 10-Q · filed 2019-05-01 | $9.68B derived: sum of 2 quarters · filed 2020-02-12 | $17.09B derived: sum of 3 quarters · filed 2020-02-12 | |
| 2017-12-31 | $6.95B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $14.36B derived: sum of 2 quarters · filed 2020-02-12 | $33.61B 10-K · filed 2020-02-12 | |
| 2017-09-30 | $7.42B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $26.66B 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | $19.24B 10-Q · filed 2018-07-27 | |||
| 2016-12-31 | $28.09B 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |